TG Therapeutics (TGTX) said Thursday it has advanced the clinical trial of anti-PD-L1 monoclonal antibody with the dosing of its first patient.
The study will evaluate the safety and tolerability of ascending doses of the antibody in patients with selected recurrent or metastatic cancers.
Secondary endpoints for this study include the evaluation or characterization of the pharmacokinetics, immunogenicity and preliminary efficacy. This study will initially enroll patients in sites across Australia and New Zealand.
“Once a recommended phase 2 dose is identified, we plan to commence a study in B-cell malignancies both as a single agent and in combination with our other pipeline products,” CEO Michael Weiss said in a statement Thursday.